JMFC
AVDL

J.M. Forbes & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

J.M. Forbes & Co’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-11,000
Closed -$88K – 88
2013
Q4 		$88K Hold
11,000
– – 0.02% 87
2013
Q3 		$72K Hold
11,000
– – 0.02% 87
2013
Q2 		$68K Buy
+11,000
New +$56.8K 0.02% 79

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

J.M. Forbes & Co's AVDL Position: Q1 2014 in Review

J.M. Forbes & Co sold out of Avadel Pharmaceuticals (AVDL) in Q1 2014, closing a stake of 11,000 shares — an estimated $88K sold.

J.M. Forbes & Co first reported a position in AVDL in Q2 2013 and held it in 3 quarters. The position peaked at $88K in Q4 2013. 52 funds tracked by Wall St. Rank hold AVDL as of Q1 2014.

  • J.M. Forbes & Co reported no remaining Avadel Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • J.M. Forbes & Co sold 11,000 Avadel Pharmaceuticals shares in Q1 2014, an estimated $88K.
  • J.M. Forbes & Co first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • J.M. Forbes & Co's Avadel Pharmaceuticals position peaked at $88K in Q4 2013.
  • 52 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2014.

Based on J.M. Forbes & Co's 13F filing for Q1 2014, filed 9 May 2014.